-
Journal of Digestive Diseases Jan 2022We aimed to describe the pattern and time trends of survival from stomach cancer worldwide from population-based cancer registers. (Review)
Review
OBJECTIVES
We aimed to describe the pattern and time trends of survival from stomach cancer worldwide from population-based cancer registers.
METHODS
A systematic search of PubMed, Web of Science, EMBASE, SEER and SinoMed for articles published up to 31 December 2020 was conducted. All eligible survival analyses of stomach cancer were collected and evaluated by countries or regions, periods, sex and age groups.
RESULTS
Our review included 76 articles on stomach cancer survival rates and found that these rates had improved globally with time, although this increase was unremarkable. The highest 5-year survival rate of 72.1% was observed in Japan (2004-2007). The 5-year relative and net survival, rates were relatively high in Korea and Japan, while they were fairly poor in Africa and India. Sex-specific survival rates were higher in women than in men in America, Europe and Oceania, whereas they were relatively low in Asia. The poorest age-specific 5-year relative and net survival rates were observed in patients aged over 75 years.
CONCLUSIONS
Over the past decades, patient prognosis of stomach cancer has gradually improved worldwide and survival rates in developed regions were higher than those in developing regions. White men and Asian women had a poorer survival than white women and Asian men. Younger patients had better survival rates than those aged over 75 years globally.
Topics: Aged; Child, Preschool; Female; Humans; Incidence; India; Male; Registries; Stomach Neoplasms; Survival Analysis; Survival Rate
PubMed: 34821032
DOI: 10.1111/1751-2980.13070 -
Asian Journal of Surgery Jan 2021The incidence and outcomes of GRC remain variable. Minority published researches have paid attention to the characteristics of GRC. This study aimed to make a systematic... (Meta-Analysis)
Meta-Analysis
The incidence and outcomes of GRC remain variable. Minority published researches have paid attention to the characteristics of GRC. This study aimed to make a systematic review and meta-analysis of the prevalence of GRC, with a focus on characteristics and survival rates of GRC. PubMed, EMBASE, and CENTRAL were searched for related clinical studies. Data were pooled using Stata 11.0, and subgroup and sensitivity analyses were performed if necessary and feasible. Moreover, SPSS (version 19.0) was used for comparing the clinical characteristics of GRC. Twenty studies were selected in this meta-analysis. The results indicated that the pooled prevalence of GRC was 2.6% (95% confidence interval (CI), 2.2-3.0%, p = 0.000). European population and American populations have a higher rate of prevalence of GRC than Chinese populations and Japan. There is no significant difference in histology and the TNM stage between the benign group and the malignant group. The five-year survival rate for GRC cases with benign primary gastric diseases is poorer than the primary gastric diseases malignant. Gastric remnant cancer is not a very rare clinical problem, especially for European and American patients. Active treatment and regular follow-up are conductive to increase 5-years survival rate.
Topics: Adult; Aged; Aged, 80 and over; China; Europe; Female; Gastrectomy; Gastric Stump; Humans; Japan; Male; Middle Aged; Prevalence; Stomach Neoplasms; Survival Rate; United States
PubMed: 32253109
DOI: 10.1016/j.asjsur.2020.03.012 -
Asian Pacific Journal of Cancer... Sep 2023Prostate cancer (Pca) is one of the most prevalent health conditions affecting men, particularly older men, and cases have increased in recent years. (Meta-Analysis)
Meta-Analysis
UNLABELLED
Prostate cancer (Pca) is one of the most prevalent health conditions affecting men, particularly older men, and cases have increased in recent years.
OBJECTIVE
This review examined the survival rate and prognostic factors of patients with Pca in Southeast Asia (SEA).
METHODS
We conducted a systematic search of three databases (PubMed, Scopus, Web of Science) and a manual search until April 1, 2022. The selected papers were evaluated using the Newcastle-Ottawa Quality Assessment Form for Cohort Studies. The review protocol was registered with PROSPERO (CRD42022326521). Pooled prevalence rates were calculated using the programme R version 4.2.1. Heterogeneity was assessed using the I2 statistic and p-value. A narrative approach was used to describe prognostic factors. Studies were selected and finalised based on the review question. The quality of the included studies was assessed.
RESULTS
A total of 11 studies were included in this review. The 1-, 3-, 5- and 10-year survival rates of SEA Pca cases were 80.8%, 51.9%, 66.1% (range 32.1-100) and 78% (range 55.9-100), respectively. Prognostic factors for Pca were discussed in terms of sociodemographic, disease-related and treatment-related aspects. The predictors of significantly lower survival were age more than 75 years, cancer detected during transurethral resection of the prostate, Gleason score more or equal to eight, high-risk group, metastases and no adjuvant radiotherapy. A meta-analysis on the pooled HR of prostate cancer could not be performed due to the heterogeneity of prognostic factors. The pooled prevalence of localised and metastatic prostate cancer in SEA countries was 39% 95% CI [20-62] and 40% 95% CI [28-53], respectively.
CONCLUSION
The survival rate in SEA countries can be determined by prognostic factors, which can be divided into sociodemographic, disease-related and treatment-related factors. Therefore, further studies are needed to improve the understanding and treatment of Pca in the region SEA.
Topics: Male; Humans; Aged; Survival Rate; Prognosis; Southeast Asian People; Transurethral Resection of Prostate; Prostatic Neoplasms
PubMed: 37774044
DOI: 10.31557/APJCP.2023.24.9.2941 -
The British Journal of Dermatology May 2024Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer that most commonly occurs in ultraviolet-exposed body sites. The epidemiology of MCC in different...
BACKGROUND
Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer that most commonly occurs in ultraviolet-exposed body sites. The epidemiology of MCC in different geographies and populations is not well characterized.
OBJECTIVES
The objective of this systematic review is to summarize evidence on the incidence, mortality and survival rates of MCC from population-based studies.
METHODS
We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from database inception to 6 June 2023. No geographic, age or date exclusions were applied. We included population-based studies of MCC that reported the incidence, survival or mortality rate, and also considered systematic reviews. A data-charting form was created and validated to identify variables to extract. Two reviewers then independently charted the data for each included study with patient characteristics, and estimates of incidence rate, mortality rate, and survival rate and assessed the quality of included studies using the Joanna Briggs Institute Checklist for Prevalence studies, Newcastle-Ottawa Scale and Assessment of Multiple Systematic Reviews. We abstracted age-, sex-, stage- and race-stratified outcomes, and synthesized comparisons between strata narratively and using vote counting. We assessed the certainty of evidence for those comparisons using the Grading of Recommendations, Assessments, Developments and Evaluations framework.
RESULTS
We identified 11 472 citations, of which 52 studies from 24 countries met our inclusion criteria. Stage I and the head and neck were the most frequently reported stage and location at diagnosis. The incidence of MCC is increasing over time (high certainty), with the highest reported incidences reported in southern hemisphere countries [Australia (2.5 per 100 000); New Zealand (0.96 per 100 000) (high certainty)]. Male patients generally had higher incidence rates compared with female patients (high certainty), although there were some variations over time periods. Survival rates varied, with lower survival and/or higher mortality associated with male sex (moderate certainty), higher stage at diagnosis (moderate-to-high certainty), older age (moderate certainty), and immunosuppression (low-to-moderate certainty).
CONCLUSIONS
MCC is increasing in incidence and may increase further given the ageing population of many countries. The prognosis of MCC is poor, particularly for male patients, those who are immunosuppressed, and patients diagnosed at higher stages or at an older age.
Topics: Carcinoma, Merkel Cell; Humans; Skin Neoplasms; Incidence; Survival Rate
PubMed: 37874770
DOI: 10.1093/bjd/ljad404 -
PloS One 2022Definitive evidence to guide clinical practice on the principles of surgery for retroperitoneal sarcomas (RPSs) is still lacking. This study aims to summarise the... (Meta-Analysis)
Meta-Analysis
BACKGROUND
Definitive evidence to guide clinical practice on the principles of surgery for retroperitoneal sarcomas (RPSs) is still lacking. This study aims to summarise the available evidence to assess the relative benefits and disadvantages of an aggressive surgical approach with contiguous organ resection in patients with RPS, the association between surgical resection margins and survival outcomes, and the role of surgery in recurrent RPS.
METHODS
We searched PubMed, the Cochrane Library, and EMBASE for relevant randomised trials and observational studies published from inception up to May 1, 2021. Prospective or retrospective studies, published in the English language, providing outcome data with surgical treatment in patients with RPS were selected. The primary outcome was overall survival (OS).
FINDINGS
In total, 47 articles were analysed. There were no significant differences in the rates of OS (HR: 0.93; 95% CI: 0.83-1.03; P = 0.574) and recurrence-free survival (HR: 1.00; 95% CI: 0.74-1.27; P = 0.945) between the extended resection group and the tumour resection alone group. Organ resection did not increase postoperative mortality (OR: 1.00; 95% CI: 0.55-1.81; P = 0.997) but had a relatively higher complication rate (OR: 2.24, 95% CI: 0.94-5.34; P = 0.068). OS was higher in R0 than in R1 resection (HR: 1.34; 95% CI: 1.23-1.44; P < 0.001) and in R1 resection than in R2 resection (HR: 1.86; 95% CI: 1.35-2.36; P < 0.001). OS was also higher in R2 resection than in no surgery (HR: 1.26; 95% CI: 1.07-1.45; P < 0.001), however, subgroup analysis showed that the pooled HR in the trials reporting primary RPS was similar between the two groups (HR, 1.14; 95% CI, 0.87-1.42; P = 0.42). Surgical treatment achieves a significantly higher OS rate than does conservative treatment (HR: 2.42; 95% CI: 1.21-3.64; P < 0.001) for recurrent RPS.
CONCLUSIONS
For primary RPS, curative-intent en bloc resection should be aimed, and adjacent organs with evidence of direct invasion must be resected to avoid R2 resection. For recurrent RPS, surgical resection should be considered as a priority. Incomplete resection remains to have a survival benefit in select patients with unresectable recurrent RPS.
Topics: Humans; Neoplasm Recurrence, Local; Prospective Studies; Retroperitoneal Neoplasms; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate
PubMed: 35901187
DOI: 10.1371/journal.pone.0272044 -
Cancer Treatment Reviews Mar 2022Little is known about placental and fetal metastases among pregnant women with cancer. Therefore, we conducted a systematic review to identify the clinical and... (Review)
Review
INTRODUCTION
Little is known about placental and fetal metastases among pregnant women with cancer. Therefore, we conducted a systematic review to identify the clinical and pathological characteristics, treatment trends and prognosis of this entity.
METHODS
We searched PubMed and EMBASE to identify the publications reporting on placental and fetal metastases through September 2021, according to the PRISMA statement. Cases of fetal and/or placental metastases among pregnant women diagnosed with metastatic cancer during pregnancy were eligible for this review. The collected information included the patients and tumor characteristics, treatment during pregnancy and prognosis including the pregnancy outcomes.
RESULTS
We identified 72 eligible cases among which placental and fetal metastases occurred in 61 (84.7%) and 24 cases (33.3%), respectively. Gestational melanoma and lung cancers were the main culprits of placental and fetal metastases. Two-thirds of the patients were diagnosed during the third trimester and only 2.7% have received cancer-specific therapy. The median maternal survival was 1 (95% CI 0.7-1.3) months post-partum and the one-year infant survival rate was 51.1%. The median gestational age was 28 weeks and the median infant age at diagnosis was 150 days. The most common fetal metastatic sites were the lungs (21.7%), scalp (17.4%), and liver (8.7%).
CONCLUSION
Fetal metastasis occurred mainly in patients with placental metastases of melanoma and lung cancer primaries and was associated with a dismal prognosis. Collecting cases from multiple institutions using a standardized case report form is necessary to increase our awareness of the occurrence of fetal metastases and the role of systemic therapies.
Topics: Female; Humans; Infant; Melanoma; Placenta; Pregnancy; Pregnancy Outcome; Prognosis; Survival Rate
PubMed: 35182890
DOI: 10.1016/j.ctrv.2022.102356 -
Annals of Global Health Jan 2020Prostate cancer is one of the most common health issues among men, especially older men. In recent years, incidences of prostate cancer is increasing. (Meta-Analysis)
Meta-Analysis
BACKGROUND
Prostate cancer is one of the most common health issues among men, especially older men. In recent years, incidences of prostate cancer is increasing.
OBJECTIVE
The aim of this study was to provide a comprehensive estimate of the survival of prostate cancer in Asian countries.
METHODS
We searched five international databases including Medline/PubMed, Scopus, Embase, Web of Knowledge and ProQuest until June 1, 2018. The Newcastle-Ottawa Quality Assessment was used to evaluate the quality of selected papers. The review protocol was registered in PROSPERO (CRD42019117044).
RESULTS
A total of 714 titles were retrieved. Thirty-seven studies met the inclusion criteria. Based on the random-effect model one-year, five-year and ten-year survival rate of prostate cancer were 81% (95% CI 77.8-84.2), 61.9% (95% CI 59.5-64.3) and 36.2% (95% CI 9.2-63.2) respectively. Survival rates based on HDI level for five-year were 30.07, 43.43 and 70.84 percent for medium, high and very high levels, respectively.
CONCLUSION
According to the results of our study, the prostate cancer survival rate in Asian countries is relatively lower than in Europe and North America.
Topics: Asia; Carcinoma; Humans; Male; Prostatic Neoplasms; Survival Rate
PubMed: 31976303
DOI: 10.5334/aogh.2607 -
Medicina (Kaunas, Lithuania) Dec 2021: Preliminary studies emphasize the similar performance of autogenous bone blocks (AUBBs) and allogeneic bone blocks (ALBBs) in pre-implant surgery; however, most of... (Review)
Review
: Preliminary studies emphasize the similar performance of autogenous bone blocks (AUBBs) and allogeneic bone blocks (ALBBs) in pre-implant surgery; however, most of these studies include limited subjects or hold a low level of evidence. The purpose of this review is to test the hypothesis of indifferent implant survival rates (ISRs) in AUBB and ALBB and determine the impact of various material-, surgery- and patient-related confounders and predictors. : The national library of medicine (MEDLINE), Excerpta Medica database (EMBASE) and Cochrane Central Register of Controlled Trials (CENTRAL) were screened for studies reporting the ISRs of implants placed in AUBB and ALBB with ≥10 participants followed for ≥12 months from January 1995 to November 2021. The review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The risk of bias was assessed via several scoring tools, dependent on the study design. Means of sub-entities were presented as violin plots. : An electronic data search resulted in the identification of 9233 articles, of which 100 were included in the quantitative analysis. No significant difference ( 0.54) was found between the ISR of AUBB (96.23 ± 5.27%; range: 75% to 100%; 2195 subjects, 6861 implants) and that of ALBB (97.66 ± 2.68%; range: 90.1% to 100%; 1202 subjects, 3434 implants). The ISR in AUBB was increased in blocks from intraoral as compared to extraoral donor sites ( 0.0003), partially edentulous as compared to totally edentulous ( 0.0002), as well as in patients younger than 45 as compared to those older ( 0.044), cortical as compared to cortico-cancellous blocks ( 0.005) and in delayed implantations within three months as compared to immediate implantations ( 0.018). The ISR of ALBB was significantly increased in processed as compared to fresh-frozen ALBB ( 0.004), but also in horizontal as compared to vertical augmentations ( 0.009). : The present findings widely emphasize the feasibility of achieving similar ISRs with AUBB and ALBB applied for pre-implant bone grafting. ISRs were negatively affected in sub-entities linked to more extensive augmentation procedures such as bone donor site and dentition status. The inclusion and pooling of literature with a low level of evidence, the absence of randomized controlled clinical trials (RCTs) comparing AUBB and ALBB and the limited count of comparative studies with short follow-ups increases the risk of bias and complicates data interpretation. Consequently, further long-term comparative studies are needed.
Topics: Bone Transplantation; Dental Implants; Hematopoietic Stem Cell Transplantation; Humans; Mouth, Edentulous; Survival Rate; United States
PubMed: 34946333
DOI: 10.3390/medicina57121388 -
Annals of Surgical Oncology Feb 2020Immunotherapy improves overall survival for patients with metatstatic melanoma and improves recurrence-free survival in the adjuvant setting, but is costly and has... (Review)
Review
BACKGROUND
Immunotherapy improves overall survival for patients with metatstatic melanoma and improves recurrence-free survival in the adjuvant setting, but is costly and has adverse effects. Little is known about the preferences of patients and clinicians regarding immunotherapy. This study aimed to identify factors important to patients and clinicians when deciding about immunotherapy for stages 2-4 melanoma.
METHODS
This study searched the Medline, EMBASE, ECONLIT, PsychINFO, and COCHRANE Systematic Reviews databases from inception to June 2018 for immunotherapy choice and preference studies. Findings were tabulated and summarized, and study reporting was assessed against recommended checklists.
RESULTS
This investigation identified eight studies assessing preferences for melanoma treatment; four studies regarding nivolumab, pembrolizumab, or ipilimumab; and four studies regarding interferon conducted in the United States, Germany, and Australia. The following 10 factors were important to decision-making: overall survival, recurrence-free survival, treatment side effects, dosing regimen, patient or payer cost, patient age, clinician or family/friend treatment recommendation, quality of life, and psychosocial effects. Overall survival was the most important factor for all respondents. The patients judged severe toxicities to be tolerable for small survival gains. The description of information about treatment harms and benefits was limited in most studies.
CONCLUSIONS
Overall survival was of primary importance to patients and clinicians considering immunotherapy. Impaired quality of life due to adverse effects appeared to be a second-order consideration. Future research is required to determine preferences for contemporary combination therapies, extended treatment durations, and avoidance of chronic side effects.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO registration number CRD42018095899.
Topics: Antineoplastic Agents, Immunological; Cost-Benefit Analysis; Decision Making; Humans; Immunotherapy; Melanoma; Patient Preference; Prognosis; Quality of Life; Survival Rate
PubMed: 31664622
DOI: 10.1245/s10434-019-07963-y -
Urology Aug 2022The purpose of this study was to determine long-term survival of inflatable penile prosthesis (PP) and identify potential factors that may influence device survival. We... (Meta-Analysis)
Meta-Analysis Review
The purpose of this study was to determine long-term survival of inflatable penile prosthesis (PP) and identify potential factors that may influence device survival. We performed a systematic review of Medline, Embase, and the Cochrane Central Register of Controlled Trials for studies of men treated with inflatable PP with at least 5 years of device survival data. We performed a random effects meta-analysis to estimate device survival at 1, 3, 5, 10, 15, and 20 years of follow-up. The robustness of the meta-analysis results was evaluated in a 1-study removed sensitivity analysis and sources of heterogeneity among studies were investigated with subgroup analysis. In 12 studies (20,161 patients; median age 57 years), PP device survival was 93.3% at 1 year, 91.0% at 3 years, 87.2% at 5 years, 76.8% at 10 years, 63.7% at 15 years, and 52.9% at 20 years. The results of the meta-analysis were not significantly influenced by single study effects in a 1-study removed sensitivity analysis. In a subgroup analysis, 5-year device survival rates were 90.6% vs 82.1% (P = .01) comparing newer vs older studies; no other patient or study design characteristic was statistically associated with device survival rates. In conclusion, the median device survival time of an inflatable PP is approximately 20 years. The factors responsible for improved device survival in newer studies remain unclear and warrant further study.
Topics: Erectile Dysfunction; Humans; Male; Middle Aged; Penile Implantation; Penile Prosthesis; Prosthesis Design; Prosthesis Failure; Survival Rate
PubMed: 35421510
DOI: 10.1016/j.urology.2022.03.026